aspirin has been researched along with mofezolac in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (40.00) | 29.6817 |
2010's | 1 (20.00) | 24.3611 |
2020's | 2 (40.00) | 2.80 |
Authors | Studies |
---|---|
Harada, S; Kakuta, H; Oda, H; Sasaki, K; Sugimoto, Y; Tai, A; Zheng, X | 1 |
Boccarelli, A; Cabral, LM; de Pádula, M; Di Mauro, GD; Ferorelli, S; Fortuna, CG; Iaselli, M; Miciaccia, M; Pati, ML; Perrone, MG; Rodrigues Pereira da Silva, LC; Sathler, PC; Scilimati, A; Souza Domingos, TF; Vacca, A; Vitale, P | 1 |
Araújo, CDCB; Bonaccorso, C; Cabral, LM; da Silva, LCRP; de Almeida, GS; de Pádula, M; Ferorelli, S; Fortuna, CG; Miciaccia, M; Perrone, MG; Sathler, PC; Scilimati, A; Souza Domingos, TF; Vitale, P | 1 |
Bhardwaj, A; Kaur, J; Wuest, F | 1 |
Amano, H; Hayashi, I; Inukai, M; Kamata, M; Kitasato, H; Majima, M; Yoshida, S; Yoshimura, H | 1 |
5 other study(ies) available for aspirin and mofezolac
Article | Year |
---|---|
Cyclooxygenase-1-selective inhibitors are attractive candidates for analgesics that do not cause gastric damage. design and in vitro/in vivo evaluation of a benzamide-type cyclooxygenase-1 selective inhibitor.
Topics: Aminopyridines; Animals; Benzamides; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Drug Evaluation, Preclinical; Magnetic Resonance Spectroscopy; Male; Mice; Mice, Inbred ICR; Molecular Structure; Rats; Rats, Sprague-Dawley; Spectrometry, Mass, Fast Atom Bombardment; Spectrophotometry, Infrared; Stomach | 2008 |
Translational impact of novel widely pharmacological characterized mofezolac-derived COX-1 inhibitors combined with bortezomib on human multiple myeloma cell lines viability.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Binding Sites; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Survival; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Humans; Isoxazoles; Multiple Myeloma; Platelet Aggregation Inhibitors; Protein Binding; Structure-Activity Relationship | 2019 |
An attempt to chemically state the cross-talk between monomers of COX homodimers by double/hybrid inhibitors mofezolac-spacer-mofezolac and mofezolac-spacer-arachidonic acid.
Topics: Algorithms; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Blood Coagulation; Chlorocebus aethiops; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Erythrocytes; Humans; Isoxazoles; Models, Molecular; Protein Binding; Protein Multimerization; Structure-Activity Relationship; Thrombosis; Vero Cells | 2021 |
Development of Fluorescence Imaging Probes for Labeling COX-1 in Live Ovarian Cancer Cells.
Topics: | 2021 |
COX-2/VEGF-dependent facilitation of tumor-associated angiogenesis and tumor growth in vivo.
Topics: Animals; Antibodies, Blocking; Aspirin; Benzenesulfonates; Carcinoma, Lewis Lung; Cyclooxygenase Inhibitors; Disease Models, Animal; Endothelial Growth Factors; Intercellular Signaling Peptides and Proteins; Isoxazoles; Lymphokines; Male; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Neovascularization, Pathologic; Nitrobenzenes; Oxazoles; Prostaglandin-Endoperoxide Synthases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sarcoma 180; Sulfonamides; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |